The DOI matches its Crossref record.
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Abstract
Objective The objective of this study was to evaluate donepezil, an acetylcholinesterase inhibitor, in the treatment of frontotemporal dementia (FTD). Methods Twelve patients with FTD who received donepezil for six months were compared with 12 FTD controls on behavioral measures. Results The groups did not differ on most variables at baseline or at six months; however, the donepezil group had greater worsening on the FTD Inventory. Four treated patients had increased disinhibited or compulsive acts, which abated with discontinuation of the medication. Conclusion There were no changes in global cognitive performance or dementia severity; however, a subgroup of patients with FTD can experience worsening of symptoms with donepezil.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, some bvFTD patients may experience behavioral or cognitive deterioration when exposed to these agents [37].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [37]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- Neary, 1998, Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology, 51, 1546, 10.1212/WNL.51.6.1546 · DOI · Paper page
- Trinh, 2003, Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis, JAMA, 289, 210, 10.1001/jama.289.2.210 · DOI · Paper page
- Cummings, 2004, Reduction of behavioral disturbances and caregiver distress by galanthamine in patients with Alzheimer's disease, Am J Psychiatry, 161, 532, 10.1176/appi.ajp.161.3.532 · DOI
- Holmes, 2004, The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease, Neurology, 63, 214, 10.1212/01.WNL.0000129990.32253.7B · DOI
- Chow, 2002, Goals in symptomatic pharmacological management of frontotemporal dementia, Am J Alzheimers Dis Other Demen, 7, 267, 10.1177/153331750201700504 · DOI
- McMurtray, 2006, Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia, Neurology, 66, 517, 10.1212/01.wnl.0000197983.39436.e7 · DOI
- Procter, 1999, Neurochemical features of frontotemporal dementia, Dement Geriatr Cogn Disord, 10, 80, 10.1159/000051219 · DOI
- Moretti, 2004, Rivastigmine in frontotemporal dementia: an open-label study, Drugs Aging, 21, 931, 10.2165/00002512-200421140-00003 · DOI
- Lampl, 2004, Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia, Ann Pharmacother, 38, 1967, 10.1345/aph.1D445 · DOI
Cited by
Sorted by citations
Bang, J., Spina, S., & Miller, B. L. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00461-4 · Cited by 1,144
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 990
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management
Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70299-4 · Cited by 496
Frontotemporal Lobar Degeneration
Rabinovici, G. D., & Miller, B. L. (2010) · CNS Drugs · doi:10.2165/11533100-000000000-00000 · Cited by 521
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H. I., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorová, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 328
“notable open-label studies with each of the ChEIs [150–152], and two open-label studies with memantine in FTLD [153]: all failed to provide robust evidence for efficacy in FTLD.”
BackgroundBeit-Arieh, I., & Tal, O. (2015) · Farewell, Revolution · doi:10.3726/978-3-653-03048-8/4 · Cited by 324
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228
Self-citationFrontotemporal lobar degeneration
Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., et al. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00447-0 · Cited by 178
Neurotransmitter deficits from frontotemporal lobar degeneration
Murley, A. G., & Rowe, J. B. (2017) · Brain · doi:10.1093/brain/awx327 · Cited by 211
“In contrast bvFTD patients taking donepezil had worsening disinhibition and compulsive behaviour (Mendez et al. , 2007).”
The Accurate Diagnosis of Early-Onset Dementia
Mendez, M. F. (2006) · The International Journal of Psychiatry in Medicine · doi:10.2190/q6j4-r143-p630-kw41 · Cited by 181
Self-citationO'Brien, J. T., & Burns, A. S. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110387547 · Cited by 166
Cognitive Impairment in Older Adults
Palmer, N. P., Ortega, B. T., & Joshi, P. (2022) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.07.010 · Cited by 200
Frontotemporal Lobar Degeneration
Schlachetzki, J. C. M. (2011) · InTech eBooks · doi:10.5772/28174
New landscape of the diagnosis of Alzheimer’s disease
Frisoni, G. B., Hansson, O., Nichols, E., Garibotto, V., Schindler, S. E., van der Flier, W. M., Jessen, F., Villain, N., Arenaza-Urquijo, E. M., Crivelli, L., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01294-2 · Cited by 143
Frontotemporal Dementia: diagnosis, Deficits and Management
Bott, N. T., Radke, A., Stephens, M. L., & Kramer, J. H. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.34 · Cited by 164
Frontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
“The behavioural symptoms improved following discontinuation of donezepil.([183])”
BackgroundTherapy and clinical trials in frontotemporal dementia: past, present, and future
Tsai, R. M., & Boxer, A. L. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13640 · Cited by 157
“Discontinuation of donepezil resulted in abatement of behavioral symptoms, which was replicated in other recent studies (Mendez et al. 2007; Arciniegas and Anderson 2013; Kimura and Takamatsu 2013).”
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Frontotemporal lobar degeneration: current perspectives
Kurz, A., Riedl, L., Mackenzie, I. R., Förstl, H., & Diehl‐Schmid, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s38706 · Cited by 123
Diagnosis and Management of Behavioral Variant Frontotemporal Dementia
Pressman, P., & Miller, B. L. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.006 · Cited by 127
“(96) Trials have not shown a convincing benefit for cholinesterase inhibitors in cognition or behavior.(97, 98) Several other drugs, including memantine, lithium and some anticonvulsants, have been tested in FTD with negative or inconclusive results.”
BackgroundMemantine in Behavioral Variant Frontotemporal Dementia: Negative Results
Vercelletto, M., Boutoleau‐Bretonnière, C., Volteau, C., Puel, M., Auriacombe, S., Sarazin, M., Michel, B., Couratier, P., Thomas-Antérion, C., Verpillat, P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101632 · Cited by 128
Treatment of Frontotemporal Dementia
Tsai, R. M., & Boxer, A. L. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0319-0 · Cited by 115
Seltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 260
“Another preliminary study reported behavioral worsening [120].”
An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration
Boxer, A. L., Lipton, A. M., Womack, K. B., Merrilees, J. J., Neuhaus, J. M., Pavlic, D., Gandhi, A. D., Red, D., Martin-Cook, K., Svetlik, D. A., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318197852f · Cited by 125
“One open-label study suggested that rivastigmine was welltolerated in FTD,(5) and a recent placebo-controlled study demonstrated in a potential benefit of galantamine in primary progressive aphasia,(6) however, experience from a number of FTLD-specialty clinics suggests that acetylcholinesterase inhibitors frequently…”
BackgroundBoccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 94
Cognitive Impairment Evaluation and Management
McCollum, L., & Karlawish, J. H. (2020) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.06.007 · Cited by 114
Cholinergic imaging in dementia spectrum disorders
Roy, R., Niccolini, F., Pagano, G., & Politis, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3349-x · Cited by 101
“Thus, cholinergic dysfunction occurs in CBD and PSP, although involving different brain regions, but it was not observed in FTD patients, whichmay explain whyAChE inhibitors are ineffective for this condition [93].”
BackgroundDiagnosis and Management of Behavioral Issues in Frontotemporal Dementia
Manoochehri, M., & Huey, E. D. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0302-7 · Cited by 101
“A case–control study of donepezil, however, showed a worsening of behavioral symptoms, including disinhibition and impulsivity [40].”
BackgroundFrontotemporal Lobar Degeneration: A Clinical Approach
Karageorgiou, E., & Miller, B. L. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381735 · Cited by 107
Boxer, A. L., & Boeve, B. F. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31815c345e · Cited by 93
Womack, K. B., Diaz-Arrastia, R., Aizenstein, H. J., Arnold, S. E., Barbas, N. R., Boeve, B. F., Clark, C. M., DeCarli, C. S., Jagust, W. J., Leverenz, J. B., et al. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.295 · Cited by 85
Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Lamb, R., Rohrer, J. D., Lees, A. J., & Morris, H. R. (2016) · Current Treatment Options in Neurology · doi:10.1007/s11940-016-0422-5 · Cited by 100
Memantine for Behavioral Disturbances in Frontotemporal Dementia: A Case Series
Swanberg, M. (2007) · Alzheimer Disease and Associated Disorders · doi:10.1097/wad.0b013e318047df5d · Cited by 72
“1 25 (20) 33 (20) 10 (7) 11 (6) 2 (2) 15 (13) 2 24 (22) 34 (20) 3 (1) 7 (3) 6 (5) 13 (13) 3 25 (24) 33 (26) 13 (11) 10 (8) 9 (3) 15 (12)”
Hirano, S., Shinotoh, H., Shimada, H., Aotsuka, A., Tanaka, N., Ota, T., Sato, K., Ito, H., Kuwabara, S., Fukushi, K., et al. (2010) · Brain · doi:10.1093/brain/awq120 · Cited by 72
“A therapeutic trial of acetylcholinesterase inhibitor in frontotemporal dementia failed to show any efficacy (Mendez et al., 2007).”
BackgroundLeroy, M., Bertoux, M., Skrobala, E., Mode, E., Adnet‐Bonte, C., Ber, I. L., Bombois, S., Cassagnaud, P., Chen, Y. S., Deramecourt, V., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00753-9 · Cited by 75
“accordance with recent data supporting lack of efficacy—or even deleterious effects in bvFTD and mFTD ([49, 50], reviewed in [51, 52]).”
BackgroundWehling, M. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03252.x · Cited by 63
An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease
the National Alzheimer’s Coordinating Center, T. A. D. N. I., Yu, Q., Initiative, T. F. L. D. N., Mai, Y., Ruan, Y., Luo, Y., Zhao, L., Fang, W., Cao, Z., Li, Y., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00757-5 · Cited by 63
“For example, cholinesterase inhibitors effective against AD may aggravate the condition of FTD patients [4].”
BackgroundKeszycki, R. M., Fisher, D. W., & Dong, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01109 · Cited by 79
“Regarding potentially inefficacious pharmacotherapy for treating disinhibition, one study found that FTD patients treated with donepezil tended to demonstrate increased socially disinhibited behavior, such as inappropriate remarks or unusual interactions with strangers (Mendez et al., 2007).”
BackgroundFrontotemporal Dementia: A Clinical Review
Sivasathiaseelan, H., Marshall, C. R., Agustus, J. L., Benhamou, E., Bond, R. L., van Leeuwen, J. E. P., Hardy, C. J. D., Rohrer, J. D., & Warren, J. D. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1683379 · Cited by 102
Off-Label Medication Use in Frontotemporal Dementia
Hu, B., Ross, L., Neuhaus, J. M., Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff‐Radford, N. R., Mendez, M. F., Miller, B. L., et al. (2010) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509356692 · Cited by 58
“One open-label study suggested that rivastigmine was well tolerated in bvFTD,(9) and a recent placebo-controlled study demonstrated a potential benefit of galantamine in logopenic variants of primary progressive aphasia (who may have underlying AD pathology(10)); however, experience from a number of FTD-specialty clin…”
BackgroundResultSelf-citationNew approaches to the treatment of frontotemporal lobar degeneration
Vossel, K. A., & Miller, B. L. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328318444d · Cited by 68
Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments
Harrison, F., Aerts, L., & Brodaty, H. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0737-7 · Cited by 69
Braun, M., Tupper, D. E., Kaufmann, P., McCrea, M., Postal, K., Westerveld, M., Wills, K., & Deer, T. M. (2011) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e3182351289 · Cited by 1,063
Kuruppu, D. K., & Matthews, B. R. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359320 · Cited by 106
Evaluation and Management of the Elderly Patient Presenting with Cognitive Complaints
Hildreth, K. L., & Church, S. D. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.11.006 · Cited by 64
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia
Kerchner, G. A., Tartaglia, M. C., & Boxer, A. L. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.6 · Cited by 57
Wauters, E., Sleegers, K., Cruts, M., & Broeckhoven, C. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00009-9 · Cited by 6
Advances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
Use of Gabapentin in the Treatment of Behavioural and Psychological Symptoms of Dementia
Kim, Y., Wilkins, K. M., & Tampi, R. R. (2008) · Drugs & Aging · doi:10.2165/00002512-200825030-00002 · Cited by 47
Huber, N., Korhonen, S., Hoffmann, D. B., Leskelä, S., Rostalski, H., Remes, A. M., Honkakoski, P., Solje, E., & Haapasalo, A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01384-8 · Cited by 58
“Donepezil in fact worsened the behavioural symptoms in a subset of FTLD patients [118], suggesting that these drugs may not be efficacious or suitable in general for symptomatic management of FTLD spectrum diseases.”
BackgroundUpdate on Frontotemporal Dementia
Arvanitakis, Z. (2010) · The Neurologist · doi:10.1097/nrl.0b013e3181b1d5c6 · Cited by 55
“However, in a more recent small study, persons taking donepezil hydrochloride had worse behavioral symptoms over a 6 month period, compared with those not taking an acetylcholinesterase inhibitor.(65) A study of 36 patients found that persons with a behavioral form of frontotemporal dementia did not benefit from galan…”
ResultBensaïdane, M. R., Beauregard, J., Poulin, S. P., Buteau, F.-A., Guimond, J. V., Bergeron, D., Verret, L., Fortin, M., Houde, M., Bouchard, R. W., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151180 · Cited by 50
Cognitive and behavioural inhibition deficits in neurodegenerative dementias
Migliaccio, R., Tanguy, D., Bouzigues, A., Sezer, I., Dubois, B., Ber, I. L., Batrancourt, B. M., Godefroy, V., & Lévy, R. (2020) · Cortex · doi:10.1016/j.cortex.2020.08.001 · Cited by 62
“Cannizzaro, 2010) and socially disinhibited behaviour (Mendez et al., 2007).”
Cholinesterase inhibitors: beyond Alzheimer’s disease
Larner, A. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.105 · Cited by 47
Bouts, M. J. R. J., Möller, C., Hafkemeijer, A., van Swieten, J. C., Dopper, E., van der Flier, W. M., Vrenken, H., Wink, A. M., Pijnenburg, Y. A. L., Scheltens, P., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170893 · Cited by 47
Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia
Bocchetta, M., Malpetti, M., Todd, E. G., Rowe, J. B., & Rohrer, J. D. (2021) · Brain Communications · doi:10.1093/braincomms/fcab158 · Cited by 53
“Across all FTD variants, atrophy of the amygdalar subnuclei relates to a wide range of behavioural and neuropsychiatric scales,14 either directly or through the deficits in the reward and emotional processing caused by bvFTD and svPPA.130,131 The medial nuclei are likely related to the development of symptoms associat…”
BackgroundInfluentialAgitation and impulsivity in mid and late life as possible risk markers for incident dementia
Bateman, D. R., Gill, S., Hu, S., Foster, E. D., Ruthirakuhan, M. T., Sellek, A. F., Mortby, M. E., Matušková, V., Ng, K. P., Tarawneh, R. M., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12016 · Cited by 39
Diagnosis and Treatment of Corticobasal Degeneration
Armstrong, M. J. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-013-0282-1 · Cited by 44
Four-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 55
Modirrousta, M., Price, B. H., & Dickerson, B. C. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.6 · Cited by 51
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 50
Clinical Subtypes of Frontotemporal Dementia
Ghosh, S., & Lippa, C. F. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513494442 · Cited by 54
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road
Sawyer, R. P., Rodriguez-Porcel, F., Hagen, M., Shatz, R., & Espay, A. J. (2017) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-017-0052-4 · Cited by 40
“In fact, some bvFTD patients may experience behavioral or cognitive deterioration when exposed to these agents [37].”
BackgroundUsing Structural and Diffusion Magnetic Resonance Imaging To Differentiate the Dementias
Suri, S., Topiwala, A., Mackay, C. E., Ebmeier, K. P., & Filippini, N. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0475-3 · Cited by 35
Gerstenecker, A. T. (2017) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx093 · Cited by 46
Use of Cholinesterase Inhibitors in Non-Alzheimer’s Dementias
Noufi, P., Khoury, R., Jeyakumar, S., & Grossberg, G. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00685-6 · Cited by 37
Treatment Options for Tauopathies
Karakaya, T., Fusser, F., Prvulovic, D., & Hampel, H. (2012) · Current Treatment Options in Neurology · doi:10.1007/s11940-012-0168-7 · Cited by 37
Prvulovic, D., & Hampel, H. (2011) · Progress in neurobiology · doi:10.1016/j.pneurobio.2011.11.009 · Cited by 37
“Based only on traditional diagnostic criteria these patients are at higher risk to be misdiagnosed and to either not receive appropriate therapy (AD drugs not applied to phenomenological atypical AD cases) or to receive medication that is not only not approved for their disease but that may even be detrimental when gi…”
BackgroundFrontotemporal dementia and pharmacologic interventions.
Kaye, E. D., Petrovic-Poljak, A., Verhoeff, N., & Freedman, M. (2010) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.22.1.19 · Cited by 36
Transition of Distinctive Symptoms of Semantic Dementia during Longitudinal Clinical Observation
Kashibayashi, T., Ikeda, M., Komori, K., Shinagawa, S., Shimizu, H., Toyota, Y., Mori, T., Ishikawa, T., Fukuhara, R., Ueno, S., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000269972 · Cited by 35
Kimura, T., & Takamatsu, J. (2013) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2012.00956.x · Cited by 34
European consensus for the diagnosis of MCI and mild dementia: Preparatory phase
Festari, C., Massa, F., Ramusino, M. C., Gandolfo, F., Nicolosi, V., Orini, S., Aarsland, D., Agosta, F., Babiloni, C., Boada, M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12798 · Cited by 38
“The currently licensed drugs (i.e., acetylcholinesterase inhibitors and memantine) is indeed indicated and effective in AD and DLB but can be detrimental to cognition in the behavioral variant of FTD, 38 while memantine is licensed in AD but poorly effective in DLB. 39 The Delphi panel endorsed an approach focused on…”
Repetitive Behaviors in Frontotemporal Dementia: Compulsions or Impulsions?
Moheb, N., Charuworn, K., Ashla, M. M., Desarzant, R. E., Chavez, D., & Mendez, M. (2018) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.18060148 · Cited by 32
Self-citationPharmacological Treatments for Frontotemporal Dementias
Nardell, M., & Tampi, R. (2014) · American Journal of Alzheimers Disease & Other Dementias · doi:10.1177/1533317513507375 · Cited by 32
“Are there concerns with the use of any of these medications in patients with FTD? In a study involving 12 patients with FTD who had received donepezil for 6 months who were compared to 12 FTD controls on behavioral measures, the investigators found that the 2 groups did not differ on most variables at baseline or at 6…”
ResultPerry, D., & Miller, B. (2013) · Seminars in neurology · doi:10.1055/s-0033-1359316 · Cited by 32
Behavioural-variant frontotemporal dementia: An update
Piguet, O., & Hodges, J. R. (2013) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642013dn70100003 · Cited by 50
Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis
Mahoney, C., Ahmed, R. M., Huynh, W., Tu, S., Rohrer, J. D., Bedlack, R., Hardiman, O. M., & Kiernan, M. C. (2021) · CNS Drugs · doi:10.1007/s40263-021-00820-1 · Cited by 38
“inhibitors do not improve cognition and may worsen behaviour [124,125].”
BackgroundDiagnosing, monitoring and managing behavioural variant frontotemporal dementia
Piguet, O., Kumfor, F., & Hodges, J. R. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01458 · Cited by 32
Jicha, G. A., & Nelson, P. T. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.9 · Cited by 33
Precision Medicine for Frontotemporal Dementia
Liu, M.-N., Lau, C.-I., & Lin, C.-P. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00075 · Cited by 20
“Cholinesterase inhibitors, such as donepezil, do not alleviate but can even exacerbate behavioral disturbance in patients with FTD (89).”
BackgroundPharmacotherapy for Neuropsychiatric Symptoms in Frontotemporal Dementia
Le, C., & Finger, E. (2021) · CNS Drugs · doi:10.1007/s40263-021-00854-5 · Cited by 26
New Approaches to the Treatment of Frontotemporal Dementia
Neylan, K. D., & Miller, B. L. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01380-6 · Cited by 42
“Cholinesterase inhibitors, one of the primary classes of medications used in the treatment of AD which include donepezil, rivastigmine, and galantamine, have been studied in FTD and show no effect on cognitive performance but can actually worsen neuropsychiatric symptoms [15, 36].”
Soucy, J.-P., Bartha, R., Bocti, C., Borrie, M., Burhan, A. M., Laforce, R., & Rosa-Neto, P. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt199 · Cited by 25
Cholinergic depletion and basal forebrain volume in primary progressive aphasia
Schaeverbeke, J., Evenepoel, C., Bruffaerts, R., van Laere, K., Bormans, G., Dries, E., Tousseyn, T., Nelissen, N., Peeters, R., Vandenbulcke, M., et al. (2016) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.027 · Cited by 25
“A therapeutic trial of donepezil in FTD failed to show any efficacy and a subgroup of patients experienced worsening of symptoms (Mendez et al., 2007).”
BackgroundTherapeutic and diagnostic challenges for frontotemporal dementia
Dâ€TMAlton, S., & Lewis, J. M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00204 · Cited by 25
“Antipsychotics and drugs targeting the cholinergic system appear to be largely Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 204 | 1 ineffective (Mendez et al., 2007).”
BackgroundNew insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia
Amin, S., Carling, G., & Gan, L. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.10.001 · Cited by 37
A Clinical Guide to Frontotemporal Dementias
Ljubenkov, P. A., & Miller, B. L. (2016) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20160018 · Cited by 36
Pharmacological treatment of frontotemporal lobar degeneration: systematic review
Portugal, M. D. G., Marinho, V., & Laks, J. (2011) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462011000100016 · Cited by 26
“Two B studies did not evaluate cognitive functions.(12,33) The quality C studies showed a significant improvement in behavior with Selegiline.”
BackgroundPanza, F., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Cirillo, N., Damiani, C., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2233892 · Cited by 22
Logroscino, G., Imbimbo, B. P., Lozupone, M., Sardone, R., Capozzo, R., Battista, P., Zecca, C., Dibello, V., Giannelli, G., Bellomo, A., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1598377 · Cited by 30
“and may also worsen behavioral symptoms [65].”
Overcoming apathy in frontotemporal dementia: challenges and future directions
Johnson, E., & Kumfor, F. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2018.01.022 · Cited by 22
Hall, G., Shapira, J., Gallagher, M., & Denny, S. S. (2013) · Journal of Gerontological Nursing · doi:10.3928/00989134-20130131-02 · Cited by 21
Self-citationWhat dementia reveals about proverb interpretation and its neuroanatomical correlates.
Kaiser, N., Lee, G., Lu, P., Mather, M. J., Shapira, J., Jimenez, E. E., Thompson, P., & Mendez, M. (2013) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2013.05.021 · Cited by 20
“Both AD and bvFTD have more rapid courses being early-onset forms of dementia (Huff et al., 1987), and are often misdiagnosed as psychiatric disorders, especially in the case of bvFTD (e.g. Mendez et al., 2007).”
Self-citationThe behavioral variant of frontotemporal dementia: An analysis of the literature and a case report.
Birkhoff, J. M., Garberi, C., & Re, L. (2016) · International Journal of Law and Psychiatry · doi:10.1016/j.ijlp.2016.04.001 · Cited by 19
“…2004; Lebert et al., 2004; Manoocherhri & Huey, 2012; Mendez, Anderson, et al., 2005; Mendez, Chen, et al., 2005; Mendez, Shapira, et al., 2005; Mendez et al., 2007; Merrilees, 2007; Merrilees & Ketelle, 2010; Mocellin et al., 2015; Moretti et al., 2003, 2004; O'Brien et al., 2011; Pijnenburg…”
Fisher, T., Schwartz, A., Greenspan, H. N., & Heinrich, T. W. (2016) · International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636579 · Cited by 19
“Acetylcholinesterase inhibitors have also been tried, but since research suggests that the behaviors can even worsen with these medications, this approach should generally be avoided.(26) Nonpharmacologic approaches are frequently used, targeting the environment and caregiver in an attempt to reduce triggering stimuli…”
BackgroundDemencia frontotemporal variante conductual: aproximación clínica y terapéutica
Fernández‐Matarrubia, M., Matías‐Guiu, J. A., Moreno‐Ramos, T., & Matías‐Guiu, J. (2013) · Neurología · doi:10.1016/j.nrl.2013.03.001 · Cited by 24
Treatment of the behavioral variant of frontotemporal dementia: a narrative review
Gambogi, L. B., Guimarães, H. C., de Souza, L. C., & Caramelli, P. (2021) · Dementia & Neuropsychologia · doi:10.1590/1980-57642021dn15-030004 · Cited by 25
Metadata
- Authors
- Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Mendez, Mario F.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 15
- Issue
- 1
- Pages
- 84-87
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2058247742
- Cited by
- 267
- References
- 0
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 9 · 2023: 13 · 2022: 11 · 2021: 23 · 2020: 14 · 2019: 19 · 2018: 13 · 2017: 16 · 2016: 19 · 2015: 6 · 2014: 19 · 2013: 18 · 2012: 11
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG19724-01, P01AG019724)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donepezil, frontotemporal dementia, acetylcholinesterase inhibitors, behavioral disinhibition, compulsive behavior, adverse drug reactions, cognitive performance
- MeSH terms
- Donepezil, Behavioral Symptoms, Cholinesterase Inhibitors, Compulsive Behavior, Dementia, Female, Humans, Indans, Male, Middle Aged, Piperidines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
